Increased activity of the complement system in cerebrospinal fluid of the patients with Non-HIV Cryptococcal meningitis

Lei Shen†, Jianming Zheng†, Yan Wang3, Mengqi Zhu2, Haoxiang Zhu2, Qi Cheng2 and Qian Li2*

Abstract

Backgrounds: Cryptococcal meningitis (CM) has been known to lead to significant morbidity and mortality. The relative contribution of the complement system in protection and pathogenesis during CM remains largely unknown. The purpose of this study was to evaluate the baseline complement component profiles in human cerebrospinal fluid (CSF) and plasma from non-HIV patients with CM, and therefore to provide insights of possible roles of the complement system in CM.

Methods: CSF and blood samples from forty two CM patients not infected with HIV and thirteen non-CM control patients (Ctrl) were retrospectively selected and evaluated from the patients admitted to the hospital with a suspected diagnosis of CM. CSF and blood samples were collected at the admission. Enzyme-linked immunosorbent assay (ELISA) for complement components, cytokine IL-12 and western blot for C3 activation were performed on CSF and plasma samples. The levels of complement C1q, factor B (FB), mannose binding lectin (MBL), C2, C3, C4, C5, C4 binding protein (C4BP), Factor I (FI), Factor H (FH), sC5b-9 in CSF and plasma samples were compared. Pearson's correlation coefficients were calculated on variables between complement components and the levels of total protein in the CSF samples.

Results: Our data demonstrated that the CSF levels of complement components of C1q, FB, MBL as well as complement pathway factors sC5b-9 and complement regulator FH were all elevated in patients with CM as compared to the controls, CSF C3 breakdown products iC3b were found in both CSF and plasma samples of the CM patients. A positive correlation was found between the levels of CSF protein and MBL, C1q or FB.

Conclusions: The activity of the complement system in CSF was increased in non-HIV patients with CM. C1q, MBL and FB are the important participants in the complement activation in CM. The relative contribution of each of the specific complement pathways and complement cascades in protection and inflammation resolution against CM warrant further investigation.

Keywords: Cryptococcal meningitis, Complement, Cryptococcus
**Background**

Cryptococcal meningitis (CM) is one of the most common diseases in HIV patients and other immune-compromised patients [1]. Over 1 million CM cases with 600,000 deaths per year in HIV patients worldwide have been reported [2]. Additionally, non-HIV related CM also contributes a significant mortality and morbidity in the developed world despite advances in antifungal therapy [1]. In China, the significant mortality and morbidity in the developed world

*Additionally, non-HIV related CM also contributes a significant mortality and morbidity in the developed world despite advances in antifungal therapy [1]. In China, the significant mortality and morbidity in the developed world.*

over 1 million CM cases with 600,000 deaths per year in HIV patients worldwide have been reported [2].

*Additionally, non-HIV related CM also contributes a significant mortality and morbidity in the developed world despite advances in antifungal therapy [1]. In China, the significant mortality and morbidity in the developed world.*

Moreover, both the classical and alternative complement pathways play a critical role in opsonophagocytosis of *C. neoformans* by neutrophils [16]. In vitro experiments demonstrated that C5a-C5aR signaling guided neutrophils to migrate to *C. neoformans*, resulting in optimal phagocytosis and subsequent killing of the organisms [17]. The complement opsonization is required in the anti-cryptococcal activity of human dendritic cells and macrophages [18, 19]. These data suggest that the major functions of the complement system are to stimulate the chemotaxis of the phagocytic effector cells and enhance the uptake of cryptococcal cells by these phagocytes. Complement functionality can be crucial to fight off and kill invading *Cryptococcus*.

To our knowledge, no study has been reported which examines the complement system activity in CSF and plasma from CM patients. The purpose of this study was to investigate whether the complement system is activated systemically and/or intrathecally during CM. The levels of the complement components in CSF and plasma samples from CM patients were determined and compared with that in the patient control group who were diagnosed with pulmonary cryptococcosis without CNS infection and inflammation involvement.

**Methods**

**Patient selection, clinical sample collection and processing**

This study was carried out from November 2014 to December 2015 at Huashan Hospital, Shanghai China. Both lumbar CSF and plasma samples were simultaneously obtained from patients with a suspected CM diagnosis at admission for routine chemistry, cytology and culture analysis. Venous blood was collected from individuals for plasma and routine blood cell and culture analysis. The remaining CSF samples were centrifuged and single use aliquots of these samples were stored at −80°C.

CM group and patient control group were retrospectively selected from the collected samples. CM group consisted of 42 patients who were ≥18 year old and not infected with HIV with a first episode of CM as diagnosed according to the criteria reported previously [20]. Confirmed cases were patients meeting the laboratory criteria with positive culture of *C. neoformans* or positive India ink smear of CSF. Possible cases were patient with positive cryptococcal antigen titer in undiluted CSF and met at least one of the following criteria: (1) abnormal laboratory tests or an increased open pressure (≥200 mmH₂O) of CSF, (2) abnormalities of cranial imaging (Computerized Tomography or Magnetic Resonance Imaging) which could not be explained by other factors. Cryptococcal antigen in CSF was determined with the Latex-*Cryptococcus* antigen detection system (Immuno-Mycologics) [21].

Control CSF or blood samples were obtained from patients who presented to the hospital with suspicion of CM but subsequently tested negative for CM or any
other pathogen in CSF with normal CSF leukocyte count and protein concentration. The control patients were diagnosed as pulmonary cryptococcosis based on histologic presence of the organism in lung biopsy specimens, or positive result of the serum cryptococcal antigen test with radiographic characteristics of pulmonary disease. [22]. The ethical and scientific committee of the College of Medicine, Fudan University approved this study.

**ELISA**

Human Complement C1q, FB, MBL, C2, C3, C4, C5, C4BP, FH, FI, sC5b-9, and cytokine Interleukin (IL) -12 were measured with commercial ELISA kits (Cusabio Biotech, Wuhan, P.R. China, R&D Systems, Minneapolis, USA, Abcam, Cambridge, UK, QuidelSan Diego, USA). Experiment protocols were followed according to the manufacturer’s instructions.

**Western blot**

For comparison of complement C3 activation in CSF and plasma samples, 20 μl of CSF and 2 μl of plasma samples were loaded on an SDS-PAGE gel. Samples were transferred to polyvinylidene difluoride (PVDF) membranes. The membranes were blocked and then incubated with mouse anti-human C3/C3b/iC3b/C3dg monoclonal antibody (1:1,000, Cedarlane, Ontario, Canada) in TBST (Tris-buffered saline supplemented with Tween 20) containing 5% dry milk at 4 °C overnight. Blots were then washed and incubated with goat anti-mouse IgG (1:15,000, LI-COR Bioscience, Nebraska, USA) diluted in TBST containing 2% dry milk. The membranes were developed with an Odyssey system (Li-COR Bioscience) according to the manufacturer’s protocol.

**Statistical analysis**

Results were graphed and analyzed using Prism 5.0 (GraphPad). Comparisons between the CM and control groups were made using unpaired t tests or Mann–Whitney tests (when the variances were significantly different). Nominal data were analyzed with Fisher exact test or Chi χ² test. Pearson’s correlation coefficients were calculated on the variability between the levels of CSF complement components and CSF total protein. In all cases, a p value of <0.05 was set as the measure of significance.

**Results**

**The clinical characteristics of participants**

The study groups consisted of 42 CM patients and 13 patients diagnosed with pulmonary cryptococcosis without CNS infection and inflammation served as Ctrl group. As shown in Table 1, there were no significant differences in gender, age, blood routine test, CSF concentration of glucose and chloride between the two groups. However, WBC counts and concentrations of protein in CSF were significantly higher in CM group than that in the Ctrl group.

**Complement components in CSF and plasma samples**

The CSF concentrations of C1q, MBL and FB of CSF in CM were greatly elevated compared to that in Ctrl, and correlated with CSF protein concentrations. We first examined the concentrations of the complement classical pathway component (C1q), the lectin pathway (MBL) and the alternative pathway (FB) in plasma and CSF samples from CM and Ctrl group. The concentrations of C1q, MBL and FB in CSF samples were significantly higher in CM group than that in Ctrl group (Fig. 1a). The mean CSF concentration of C1q was 1673.14 ng/ml in the CM group, but only 162.72 ng/ml in the Ctrl group. The mean concentration of MBL was 5.11 ng/ml in the CM group, but 0.38 ng/ml in the Ctrl group. The mean concentration of FB was 5.73 ng/ml in the CM group, but 1.88 ng/ml in the Ctrl group. Moreover, CSF concentrations of C1q, MBL and FB were found to be correlated to CSF protein levels (r = 0.5804 for C1q, p-value =0.0479, r = 0.7061 for MBL, p-value = 0.0003, and r = 0.6716, p-value =0.009). However, There were no

| Table 1 The clinical characteristics of participants |
|---------------------------------------------------|
|                       | Ctrl       | CM         | p value   |
| Gender, M/F           | 9/4        | 28/14      | 0.5740    |
| Age (means ± SEM, years old) | 46.38 ± 11.15 | 44.86 ± 14.14 | 0.7233     |
| Blood WBC (means ± SEM, 10⁹/mm³) | 6.98 ± 2.67 | 8.20 ± 3.75 | 0.2981     |
| CSF WBC (median, 10³/mm³) | 2          | 9          | 0.0022     |
| CSF Protein (median, mg/l) | 3875       | 883        | 0.0006     |
| Blood Sugar (median, mmol/l) | 5.4        | 6.9        | 0.5631     |
| CSF Glucose (median, mmol/l) | 2.65       | 2.70       | 0.4762     |
| CSF Chloride (median, mmol/l) | 121        | 120        | 0.3703     |

CM: cryptococcal meningitis group
Ctrl: control group
The concentrations of the plasma concentrations of C1q, MBL and FB between the CM and Ctrl groups (Fig. 1b), suggesting that increased concentrations of C1q, FB and MBL in CSF is a localized phenomenon.

The concentrations of complement components C2, C3, C4 and C5 in plasma and CSF samples
We further examined the concentrations of C2, C3, C4 and C5 in the plasma and CSF samples. There were no statistical significances of the concentrations of these complement factors in both plasma and CSF samples between the two groups (Fig. 2a and b).

C3 activation in CSF and plasma in CM
The complement system activation is mediated through the CP, AP and LP pathways. Each pathway converges at the C3 convertase level resulting in C3 cleavage. To further assess whether the C3 activation is involved in CM, levels of C3 breakdown products in CSF and those in simultaneously collected blood plasma samples were evaluated by Western blot. C3 cleavage fragments iC3b was detected in CM group from both plasma and CSF samples (Fig. 3).

The concentrations of sC5b-9 in plasma and CSF samples
To determine the complement terminal pathway activation, we examined the concentrations of sC5b-9 in plasma and CSF samples in Ctrl and CM groups. There was no significant difference in plasma concentrations of sC5b-9 between the two groups. However, the CSF concentrations of sC5b-9 in CM group was significantly higher than that in the Ctrl group ($p = 0.0064$) (Fig. 4).

The concentrations of C4BP, FI and FH in plasma and CSF
The complement system is regulated by some key fluid regulators, such as C4BP, FI and FH. We next measured the concentrations of these factors in plasma and CSF samples. There were no significant differences in the plasma concentrations of C4BP, FI and FH expressed between Ctrl and CM groups (Fig. 5a). The concentrations of C4BP and FI in CSF were also similar in both Ctrl and CM groups (Fig. 5b). However, the CSF concentrations of FH increased significantly in CM group compared to the Ctrl group ($p = 0.0303$) (Fig. 5b).

The levels of IL-12 in the plasma and in CSF samples
We next investigated the levels of IL-12 because it may play an important role in host defense in CM [23]. As
shown in Fig. 6, though the plasma levels of IL-12 were similar between the Ctrl and CM groups, the CSF levels of IL-12 were significantly higher in CM group than that in Ctrl group ($p = 0.0121$) (Fig. 6).

Discussion
In this study, we showed elevated CSF concentrations of C1q, MBL, FB, sc5b-9 and FH in CM patients compared to that in the control group and the common complement pathway factors iC3b in both CSF and plasma samples of CM patients. Our data suggest that the increased CSF complement system activity might indicate its important roles in host defense and pathogenesis in CM.

Though the importance of the complement system to C. neoformans infection is well established, it is not clear how the complement system responds to pathogens in CM clinically. The brain may represent its own characteristics not like other organ when infected with Cryptococcus. There are few publications in this field. Our data demonstrated that complement components including the initiators of three complement pathways (C1q, FB and MBL), other complement factors (C2, C3, C4, C5) and regulators (FH, FI, C4BP) were present in CSF in CM. Moreover, CSF levels of C1q, MBL, and FB were significantly higher compared with that in control group. In this study, we showed C3 and the complement terminal pathways were activated in CSF during CM. Cleavage of C3 generates the key opsonins, C3b and iC3b for phagocytosis [24]. Activation of the complement terminal pathway results in releasing anaphylatoxins C5a, and formation of a membrane attack complex to lyse the target cells. Meanwhile, sc5b-9 as the final product of complement activation was significantly higher in CSF in CM group than that in the control group. Our results were similar with the report from Mook-Kanamori et.al [6], which demonstrated that CSF levels of C1q, MBL, FH and sc5b-9 were significantly elevated during pneumococcal and meningococcal meningitis. Thus our data suggest an important role of the complement system in host protection against CM as well. C1q, MBL and FB each separately initiates the classical, lectin and alternative pathway, and plays a key role in the innate immune system. C1q also take part in the clearance of apoptotic cells during inflammation resolution [25, 26].

The differences of complement components between the CM and Ctrl groups were only detected in CSF samples, not in the plasma samples. This indicates that local inflammatory responses impact significantly on activity of the complement system in CSF. The brain as a well-developed organ of CNS is shielded by the blood–brain-barrier (BBB) with tight junction formations. BBB is a structural and functional barrier formed by the microvascular endothelium, astrocytes and pericytes. The complement system has taken part in various developmental and regenerative processes, and is integrated with multiple biological systems and pathways in many researches [27]. We think that the elevated CSF complement factors of patients with CM have leaked from the plasma because the CSF complement levels of C1q, MBL and FB were significantly correlated with the total concentrations of CSF protein. It is well known that a non-specific increase in permeability of the blood-CSF barrier during meningitis results in a rise in CSF protein concentrations including all the plasma proteins [28]. However, complement factors can be synthesized locally in the CNS [29]. Astrocyte and glial cell are the main sources of complement in CNS [30, 31]. Previous study using Reibergram method demonstrates that C3 and C4 were synthesized locally during bacterial meningitis. Further studies using Reibergram are needed to determine whether intrathecal synthesis of complement factors is, at least in part, responsible for the increased levels of CSF complement factors in CM.

However, complement has been described as a double-edged sword since activation of the complement system...
significantly contributes to the pathogenesis of various acute and chronic inflammatory diseases [32]. Adequate regulation of the complement system is a central component of the system’s ability to control unintended complement activation on host cells. The expression of regulator also can be detected in CSF, such as C4BP, FI, and FH. Their amounts are nearly the same in CSF and plasma. However, CSF FH concentrations were obviously higher in CM than that in the control group. FH regulates the AP both in the fluid phase and on cell surfaces. Expression of FH regulators indicates the balance also exits to control the degree of activation of complement. The role of the complement system activation in host defense and neuro-inflammation in CM is not fully understood. Elucidating which components of the complement system are important in both protective and inflammatory roles in CM to drive development of CM-specific immunotherapies.

It is well known that a Th1-driven cell-mediated response is necessary for the control of C. neoformans infections. Beenhouwer and his colleagues found that the relative inherent susceptibilities of the mouse strains to C. neoformans were as follows: IL-12−/− > IL-6−/− > C57BL/6 >> IL-10−/− [33]. In the present study, the CSF concentrations of IL-12 were significantly higher in CM group than that in Ctrl group. In mirror with other reports, our data indicated a protective role of IL-12 in CM. Exploring underlying mechanisms in regulation of IL-12 production and the cross talk with the complement system in CM would provide a new perspective for treatment of CM.

Conclusion
In conclusion, our data revealed the presence of the complement components and the complement activation in CSF in non-HIV patients with CM, and suggested an important role of complement factors C1q, MBL, FB, FH and sCSb-9 in the pathogenesis of CM. Further studies are warranted to confirm the pathophysiological role of these complement factors in CM and to stimulate the development of new therapeutic strategies for CM by directing treatment to specific pathways within the complement cascade.

Abbreviations
AP: Alternative pathway; BBB: Blood-brain-barrier; C1INH: C1 inhibitor; C4BP: C4 binding protein; CM: Cryptococcal meningitis; CNS: Central nervous system; CP: Classical pathway; CSF: Cerebrospinal fluid; Ctrl: Control patients; ELISA: Enzyme-linked immunosorbent assay; FB: Factor B; FH: Factor H; FI: Factor I; IL: Interleukin; LP: Lectin pathway; MBL: Mannose binding lectin; PVDF: Polyvinylidene difluoride; SDS-PAGE: Sodium dodecyl sulfate polyacrylamide gel electrophoresis; TBST: Tris-buffered saline

Acknowledgements
We thank Dr. Hua Hua Tong from the Ohio State University for helpful suggestions and criticism.
Funding
The study was supported by Shanghai Health and Family Planning Commission (award number 2014040578).

Availability of data and materials
Data supporting our findings is contained within the manuscript. Data is available from the corresponding author upon request. Identifying/confidential patient data however will not be shared.

Authors’ contributions
LS, JZ performed the experiments. YW, MZ aided in the data analysis as well as drafted the manuscript. HZ, QC contributed reagents/material. QL conceived, designed, executed, evaluated the experiments and wrote the paper. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
The ethical and scientific committee of the College of Medicine, Huashan Hospital, Fudan University approved this study.

Author details
1Department of Thoracic Intensive Care Units, Shanghai Pulmonary Hospital, Shanghai, China. 2Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China. 3Central Laboratory, Huashan Hospital, Fudan University, Shanghai, China.

Received: 10 August 2016 Accepted: 10 December 2016
Published online: 04 January 2017

References
1. Sloan DJ, Paris V. Cryptococcal meningitis: epidemiology and therapeutic options. Clin Epidemiol. 2014;6:169–82.
2. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23(4):525–30.
3. Fang W, Fa Z, Liao W. Epidemiology of Cryptococcus and cryptococcosis in China. Fungal Genet Biol. 2015;78:7–15.
4. Merle NS, Hoe R, Halbwachs-Mecarelli L, Fremeaux-Bacqu V, Roumenina LT. Complement system part II: role in immunity. Front Immunol. 2015;6:257.
5. Rupprecht TA, Angelte B, Klein M, Heesemann J, Pfister HW, Botto M, et al. Complement C1q and C3 are critical for the innate immune response to Streptococcus pneumoniae in the central nervous system. J Immunol. 2007;178(3):1811–9.
6. Mook-Kanamori BB, Brouwer MC, Geldhoff M, Ende A, van de Beek D. Cerebrospinal fluid complement activation in patients with pneumococcal and meningococcal meningitis. J Infect. 2014;68(6):542–7.
7. Woehrl B, Brouwer MC, Murr C, Heckenberg SG, Baas F, Pfister HW, et al. Complement component 3 contributes to poor disease outcome in humans and mice with pneumococcal meningitis. J Clin Invest. 2011;121(10):3943–53.
8. Goonetilleke UN, Scarborough M, Ward SA, Hussain S, Kadioglu A, Gordon SB. Death is associated with complement C3 depletion in cerebrospinal fluid of patients with pneumococcal meningitis. MBio. 2012;3(2):e00272–11.
9. Munshi MA, Relia A, Poeta MD. Fungal Infection of the CNS. In: García-Moncó JC, editor. London: CNS Infections; 2014. p.119–37.
10. Voezz K, May RC. Cryptococcal interactions with the host immune system. Eukaryot Cell. 2012;9(6):835–46.
11. Rhodes JC, Wicker LS, Urba WJ. Genetic control of susceptibility to Cryptococcus neoformans in mice. Infect Immun. 1980;29(2):494–9.
12. Diamond RD, May JE, Kane M, Frank MM, Bennett JE. The role of late complement components and the alternate complement pathway in experimental meningococcal disease. Proc Soc Exp Biol Med. 1972;144(1):1312–5.
13. Rhodes JC. Contribution of complement component C5 to the pathogenesis of experimental murine cryptococcosis. Sabouraudia. 1985;23(3):225–34.
14. Machet AM, Bennett JE, Gadek JE, Frank MM. Complement depletion in cryptococcal sepsis. J Immunol. 1978;120(5):1686–90.
15. Truelson K, Young T, Kozel TR. In vivo complement activation and binding of C3 to encapsulated Cryptococcus neoformans. Infect Immun. 1992;60(9):3937–9.
16. Diamond RD, May JE, Kane MA, Frank MM, Bennett JE. The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection. J Immunol. 1974;112(6):2280–70.
17. Sun D, Zhang M, Liu G, Wu H, Zhu X, Zhou H, et al. Real-time imaging of interactions of neutrophils with Cryptococcus neoformans demonstrates a crucial role of complement C5a-C5aR signaling. Infect Immun. 2015;84(1):216–29.
18. Kozel TR, Hightson B, Stratton CJ. Localization on encapsulated Cryptococcus neoformans of serum components opsonic for phagocytosis by macrophages and neutrophils. Infect Immun. 1984;43(2):574–9.
19. Kelly RM, Shen J, Yauch LE, Levitt SM. Opsonic requirements for dendritic cell-mediated responses to Cryptococcus neoformans. Infect Immun. 2005;73(1):592–8.
20. Ou XT, Wu JQ, Zhu LP, Guan M, Xu B, Hu XP, et al. Genotypes coding for mannose-binding lectin deficiency correlated with cryptococcal meningitis in HIV-uninfected Chinese patients. J Infect Dis. 2011;202(11):1686–91.
21. Perfett JR, Dismukes WE, Dromer F, Goldman DJ, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2010;50(3):291–322.
22. De Pauw B, Waldb T, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813–21.
23. Decken K, Köhler G, Palmer-Lehmann K, Wunderlin A, Mattner F, Magram J, et al. Interleukin-12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans. Infect Immun. 1998;66(10):4994–5000.
24. Li Q, Li YX, Douhttt K, Stahl GL, Thurman JM, Tong HH. Role of the alternative and classical complement activation pathway in complement mediated killing against Streptococcus pneumoniae colony opacity variants during acute pneumococcal otitis media in mice. Microbes Infect. 2012;14(14):1308–18.
25. Kruser L, Madhukaran SP, Shastri A, Sarao A, Ferluga J, Al-Mozaini M, et al. Emerging and novel functions of complement protein C1q. Front Immunol. 2015;6:317.
26. Fraser DA, Laust AK, Nelson EL, Tenner AJ. C1q differentially modulates phagocytosis and cytokine responses during ingestion of apoptotic cells by human monocytes, macrophages, and dendritic cells. J Immunol. 2009; 183(10):6757–85.
27. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11(8):875–9.
28. Davson H, Oldendorf WH. Symposium on membrane transport. Transport in the central nervous system. Proc R Soc Med. 1967;60(4):326–9.
29. Alawieh A, Elvington A, Tomlinson S. Complement in the homeostatic and ischemic brain. Front Immunol. 2015;6:417.
30. Lévi-Stauss M, Mallat M. Primary cultures of murine astrocytes produce C3 and factor B, two components of the alternative pathway of complement activation. J Immunol. 1987;130(7):2361–6.
31. Gasque P, Fontaine M, Morgan BP. Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. J Immunol. 1995;154(9):4726–33.
32. Charchaflieh J, Wei J, Labaze G, Hou YJ, Babarsh B, Stutz H, et al. The role of complement system in septic shock. Clin Dev Immunol. 2012;2012:407324.
33. Beenhouwer DO, Shapiro S, Feldmesser M, Casadevall A, Scharff MD. Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans. Infect Immun. 2001;69(10):6445–55.